Lingtak-Neander Chan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lingtak-Neander Chan has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Ada Z. Koch
Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Illinois 60612, USA
1 shared publicationJawed Abubaker
Department of Medicine, Section of Respiratory & Critical Care Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois
1 shared publicationV. Theodore Barnett
Department of Medicine, Section of Respiratory & Critical Care Medicine, College of Medicine, University of Illinois at Chicago, Chicago, Illinois
1 shared publication
Latest Publications
- 1 March 2004
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 7 (2) , 207-212
Nutritional support in acute renal failure
Acute renal failure is commonly present in patients with sepsis, shock, trauma, burn injury, or multi-organ dysfunction syndrome. Acute renal failure is an independent risk factor contributing to increased hospital mortality. The major complications associated with acute renal failure include metabolic derangement and protein catabolism. The purpose of this article is to review the literature between 2001 and December 2003, to determine whether newer studies have provided a better understanding of the optimization of caloric and protein delivery to critically ill patients with acute renal failure receiving continuous renal replacement therapy. Continuous renal replacement therapy is now widely used in the intensive care unit to manage patients with acute renal failure, because it is better tolerated than intermittent hemodialysis by patients who are hemodynamically unstable. Although continuous renal replacement therapy is highly efficient in the removal of toxins and metabolic wastes, it may also lead to an excessive loss of nutrients, which include intact protein and amino acids. Data describing the optimal nutritional support regimen for patients receiving continuous renal replacement therapy are very limited. The results and findings from this review may help clinicians to individualize caloric and protein delivery for patients with acute renal failure. The ultimate goal is to tailor the regimen towards the needs of each individual patient in order to maximize the benefit of nutritional support, in the hope of improving patient survival.
- 1 March 2004
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 7 (2) , 207-212
Nutritional support in acute renal failure
Acute renal failure is commonly present in patients with sepsis, shock, trauma, burn injury, or multi-organ dysfunction syndrome. Acute renal failure is an independent risk factor contributing to increased hospital mortality. The major complications associated with acute renal failure include metabolic derangement and protein catabolism. The purpose of this article is to review the literature between 2001 and December 2003, to determine whether newer studies have provided a better understanding of the optimization of caloric and protein delivery to critically ill patients with acute renal failure receiving continuous renal replacement therapy. Continuous renal replacement therapy is now widely used in the intensive care unit to manage patients with acute renal failure, because it is better tolerated than intermittent hemodialysis by patients who are hemodynamically unstable. Although continuous renal replacement therapy is highly efficient in the removal of toxins and metabolic wastes, it may also lead to an excessive loss of nutrients, which include intact protein and amino acids. Data describing the optimal nutritional support regimen for patients receiving continuous renal replacement therapy are very limited. The results and findings from this review may help clinicians to individualize caloric and protein delivery for patients with acute renal failure. The ultimate goal is to tailor the regimen towards the needs of each individual patient in order to maximize the benefit of nutritional support, in the hope of improving patient survival.
- 1 May 2002
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 5 (3) , 327-332
Drug-nutrient interaction in clinical nutrition
Drug-nutrient interactions have been recognized for decades. It is known that improper management of some of these interactions may lead to therapeutic failure or cause serious adverse effects to the patients. While most of the known drug-nutrient interactions involve changes in oral bioavailabilities and absorption of the offending compounds, recent investigations suggest that different mechanisms also exist. A mechanism-derived classification system for drug-nutrient interactions has only recently been developed. This system should facilitate the future research and development of practice guidelines in the identification and management of important interactions.
- 1 May 2002
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 5 (3) , 327-332
Drug-nutrient interaction in clinical nutrition
Drug-nutrient interactions have been recognized for decades. It is known that improper management of some of these interactions may lead to therapeutic failure or cause serious adverse effects to the patients. While most of the known drug-nutrient interactions involve changes in oral bioavailabilities and absorption of the offending compounds, recent investigations suggest that different mechanisms also exist. A mechanism-derived classification system for drug-nutrient interactions has only recently been developed. This system should facilitate the future research and development of practice guidelines in the identification and management of important interactions.
- 17 January 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (1) , 118-122
Use of Thrombolytic Therapy to Treat Heparin‐Refractory Pulmonary Embolism in a Menstruating Patient
A 26‐year‐old woman developed an acute pulmonary embolism at the beginning of her menstrual cycle and was admitted to the hospital. When she failed initial standard treatment with heparin, the only other therapeutic option was a thrombolytic agent such as recombinant tissue plasma activator (rt‐PA). Use of these agents, however, carries a large risk of major bleeding complications and brings concern of increased menstrual blood flow and duration. A literature search of the use of thrombolytic agents in menstruating patients found only limited reports. Our patient responded well to rt‐PA therapy. Her hemoglobin levels remained stable, and she experienced no bleeding complications. Careful monitoring and caution are recommended when administering thrombolytic agents to menstruating patients.
- 17 January 2002
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 22 (1) , 118-122
Use of Thrombolytic Therapy to Treat Heparin‐Refractory Pulmonary Embolism in a Menstruating Patient
A 26‐year‐old woman developed an acute pulmonary embolism at the beginning of her menstrual cycle and was admitted to the hospital. When she failed initial standard treatment with heparin, the only other therapeutic option was a thrombolytic agent such as recombinant tissue plasma activator (rt‐PA). Use of these agents, however, carries a large risk of major bleeding complications and brings concern of increased menstrual blood flow and duration. A literature search of the use of thrombolytic agents in menstruating patients found only limited reports. Our patient responded well to rt‐PA therapy. Her hemoglobin levels remained stable, and she experienced no bleeding complications. Careful monitoring and caution are recommended when administering thrombolytic agents to menstruating patients.
- 1 May 2001
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 25 (3) , 132-141
Drug‐Nutrient Interactions in Transplant Recipients
Drug‐nutrient interaction refers to an alteration of kinetics or dynamics of a drug or a nutritional element, or a compromise in nutritional status as a result of the addition of a drug. The potentials for drug—nutrient interaction increase with the number of drugs taken by the patient. Organ transplant recipients are therefore at high risk for drug‐nutrient interactions because multiple medications are used to manage graft rejection, opportunistic infections, and other associated complications. Unrecognized or unmanaged drug‐nutrient interactions in this patient population can have an adverse impact on their outcomes. This paper reviews the importance of recognizing drug‐nutrient interaction when using cyclosporine‐based regimens.(Journal of Parenteral and Enteral Nutrition25:132–141, 2001)
- 1 May 2001
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 25 (3) , 132-141
Drug‐Nutrient Interactions in Transplant Recipients
Drug‐nutrient interaction refers to an alteration of kinetics or dynamics of a drug or a nutritional element, or a compromise in nutritional status as a result of the addition of a drug. The potentials for drug—nutrient interaction increase with the number of drugs taken by the patient. Organ transplant recipients are therefore at high risk for drug‐nutrient interactions because multiple medications are used to manage graft rejection, opportunistic infections, and other associated complications. Unrecognized or unmanaged drug‐nutrient interactions in this patient population can have an adverse impact on their outcomes. This paper reviews the importance of recognizing drug‐nutrient interaction when using cyclosporine‐based regimens.(Journal of Parenteral and Enteral Nutrition25:132–141, 2001)